Pharmala Biotech Holdings Inc. MDMA
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 206.87% | 107.45% | 116.63% | -42.75% | -70.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 206.87% | 107.45% | 116.63% | -42.75% | -70.81% |
| Cost of Revenue | 302.41% | 173.34% | 159.62% | -64.83% | -134.60% |
| Gross Profit | 83.94% | 39.35% | 34.29% | -39.08% | -47.41% |
| SG&A Expenses | 5.88% | -8.64% | 42.63% | 68.55% | 46.94% |
| Depreciation & Amortization | 8.71% | 21.11% | 35.93% | 62.40% | 76.79% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.86% | 4.95% | 65.97% | 57.65% | 22.36% |
| Operating Income | 23.19% | 19.72% | -51.85% | -236.93% | -327.43% |
| Income Before Tax | 19.65% | 14.94% | -52.52% | -155.94% | -188.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.65% | 14.94% | -52.52% | -155.94% | -188.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.65% | 14.94% | -52.52% | -155.94% | -188.86% |
| EBIT | 23.19% | 19.72% | -51.85% | -236.93% | -327.43% |
| EBITDA | 22.31% | 20.08% | -53.35% | -251.63% | -430.62% |
| EPS Basic | 25.17% | 23.29% | -33.03% | -129.41% | -157.89% |
| Normalized Basic EPS | 25.56% | 23.60% | -33.33% | -128.57% | -157.14% |
| EPS Diluted | 25.17% | 23.29% | -33.03% | -129.41% | -157.89% |
| Normalized Diluted EPS | 25.56% | 23.60% | -33.33% | -128.57% | -157.14% |
| Average Basic Shares Outstanding | 8.73% | 12.41% | 15.06% | 12.39% | 11.16% |
| Average Diluted Shares Outstanding | 8.73% | 12.41% | 15.06% | 11.78% | 10.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |